CA1297909C - 1-(aminophenyl)-2-aminoethanone derivatives, the method for their preparation and their use in therapy - Google Patents
1-(aminophenyl)-2-aminoethanone derivatives, the method for their preparation and their use in therapyInfo
- Publication number
- CA1297909C CA1297909C CA000488994A CA488994A CA1297909C CA 1297909 C CA1297909 C CA 1297909C CA 000488994 A CA000488994 A CA 000488994A CA 488994 A CA488994 A CA 488994A CA 1297909 C CA1297909 C CA 1297909C
- Authority
- CA
- Canada
- Prior art keywords
- crl
- aminophenyl
- hour
- dose
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- ACTLYQCWIWMUSY-UHFFFAOYSA-N 2-amino-1-(2-aminophenyl)ethanone Chemical class NCC(=O)C1=CC=CC=C1N ACTLYQCWIWMUSY-UHFFFAOYSA-N 0.000 title claims abstract 3
- 238000000034 method Methods 0.000 title claims description 10
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- XCQFELSRKBMTCK-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(propan-2-ylamino)ethanone Chemical compound CC(C)NCC(=O)C1=CC=C(N)C=C1 XCQFELSRKBMTCK-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 abstract description 4
- 229940005513 antidepressants Drugs 0.000 abstract description 4
- 238000003381 deacetylation reaction Methods 0.000 abstract description 2
- 230000006196 deacetylation Effects 0.000 abstract 1
- 239000000021 stimulant Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 30
- 230000000694 effects Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 206010042008 Stereotypy Diseases 0.000 description 15
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 12
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 11
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 11
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 11
- 229960003147 reserpine Drugs 0.000 description 11
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 11
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229940025084 amphetamine Drugs 0.000 description 9
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 229960004046 apomorphine Drugs 0.000 description 8
- 230000002631 hypothermal effect Effects 0.000 description 8
- 206010021113 Hypothermia Diseases 0.000 description 6
- 229960002319 barbital Drugs 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 230000004899 motility Effects 0.000 description 6
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 5
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960001344 methylphenidate Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000003291 dopaminomimetic effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CMVYIGDFKMCMAV-UHFFFAOYSA-N 2-amino-1-(4-aminophenyl)-3-methylbutan-1-one Chemical compound NC1=CC=C(C=C1)C(C(C(C)C)N)=O CMVYIGDFKMCMAV-UHFFFAOYSA-N 0.000 description 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 239000000842 neuromuscular blocking agent Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- -1 1-(4-acetylaminophenyl)-2-isopropyl--aminoethanone hydrochloride Chemical compound 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- CQVKMVQRSNNAGO-UHFFFAOYSA-N 2-[4-formyl-3-methyl-n-(2-methylsulfonyloxyethyl)anilino]ethyl methanesulfonate Chemical compound CC1=CC(N(CCOS(C)(=O)=O)CCOS(C)(=O)=O)=CC=C1C=O CQVKMVQRSNNAGO-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- REEUVFCVXKWOFE-UHFFFAOYSA-K gallamine triethiodide Chemical compound [I-].[I-].[I-].CC[N+](CC)(CC)CCOC1=CC=CC(OCC[N+](CC)(CC)CC)=C1OCC[N+](CC)(CC)CC REEUVFCVXKWOFE-UHFFFAOYSA-K 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical compound Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8412966 | 1984-08-20 | ||
| FR8412966A FR2569185B1 (fr) | 1984-08-20 | 1984-08-20 | Derives de 1-(aminophenyl)-2-amino-ethanone, procede de preparation et utilisation en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1297909C true CA1297909C (en) | 1992-03-24 |
Family
ID=9307109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000488994A Expired - Lifetime CA1297909C (en) | 1984-08-20 | 1985-08-19 | 1-(aminophenyl)-2-aminoethanone derivatives, the method for their preparation and their use in therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4816489A (forum.php) |
| EP (1) | EP0174888B1 (forum.php) |
| JP (1) | JPS6165849A (forum.php) |
| AT (1) | ATE27698T1 (forum.php) |
| CA (1) | CA1297909C (forum.php) |
| DE (1) | DE3560237D1 (forum.php) |
| DK (1) | DK378785A (forum.php) |
| ES (1) | ES8605467A1 (forum.php) |
| FR (1) | FR2569185B1 (forum.php) |
| GR (1) | GR851995B (forum.php) |
| IE (1) | IE58519B1 (forum.php) |
| PT (1) | PT80993B (forum.php) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
| IL156669A0 (en) * | 2003-06-26 | 2004-01-04 | Neurim Pharma 1991 | 2-aminobenzoyl derivatives |
| KR101306635B1 (ko) | 2005-06-27 | 2013-10-11 | 밸리언트 인터내셔널(바베이도스) 에스알엘 | 부프로피온염의 개질-방출 제형 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH175266A (fr) * | 1932-11-02 | 1935-02-15 | J G Brill Societe Anonyme Comp | Châssis pour voiture légère de chemins de fer. |
| CH175267A (de) * | 1934-05-03 | 1935-02-28 | Leuenberger Faessler Hans | Für verschiedene Radabstände einstellbare Radachse für Selbsthalterpflüge. |
| US2128255A (en) * | 1934-12-22 | 1938-08-30 | Gen Aniline Works Inc | Azo dyestuffs |
| GB453437A (en) * | 1935-03-07 | 1936-09-07 | Ig Farbenindustrie Ag | Improvements in the manufacture and production of azo dyestuffs |
| US2151518A (en) * | 1935-03-07 | 1939-03-21 | Gen Aniline Works Inc | Azo dyestuff |
| NL246399A (forum.php) * | 1958-12-19 | |||
| BE622585A (forum.php) * | 1961-09-18 | |||
| US3151124A (en) * | 1961-11-20 | 1964-09-29 | Ciba Geigy Corp | Alpha oxy-beta alkyl-gamma tertiary amino-alpha phenyl propanes |
| US3171858A (en) * | 1963-08-30 | 1965-03-02 | Parke Davis & Co | alpha-ethylamino-o-methylisobutyrophenone |
| AT252214B (de) * | 1963-10-09 | 1967-02-10 | Bayer Ag | Verfahren zur Herstellung von neuen D(-)-N-Akyl-1-phenyl-2-aminoäthanolen und/oder deren Salzen |
| US3225096A (en) * | 1964-03-02 | 1965-12-21 | Lilly Co Eli | N-cyclopropylamine aralkanone and aralkanol amine derivatives |
| DE1242241B (de) * | 1964-04-08 | 1967-06-15 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von substituierten Phenyl-alpha-aminoketonen und deren Saeureadditionssalzen bzw. deren optischen Antipoden |
| BE759838A (fr) * | 1969-12-04 | 1971-06-03 | Wellcome Found | Cetones a activite biologique |
| US4063025A (en) * | 1975-02-05 | 1977-12-13 | Yamanouchi Pharmaceutical Co., Ltd. | 4-Substituted amino-α-aminomethylbenzyl alcohol derivatives |
| JPS5690044A (en) * | 1979-12-21 | 1981-07-21 | Shionogi & Co Ltd | 2- secondary aminoacetyl aniline |
-
1984
- 1984-08-20 FR FR8412966A patent/FR2569185B1/fr not_active Expired
-
1985
- 1985-08-07 EP EP85401610A patent/EP0174888B1/fr not_active Expired
- 1985-08-07 DE DE8585401610T patent/DE3560237D1/de not_active Expired
- 1985-08-07 AT AT85401610T patent/ATE27698T1/de active
- 1985-08-12 IE IE198685A patent/IE58519B1/en not_active IP Right Cessation
- 1985-08-16 GR GR851995A patent/GR851995B/el unknown
- 1985-08-16 ES ES546860A patent/ES8605467A1/es not_active Expired
- 1985-08-19 CA CA000488994A patent/CA1297909C/en not_active Expired - Lifetime
- 1985-08-20 JP JP60181143A patent/JPS6165849A/ja active Pending
- 1985-08-20 PT PT80993A patent/PT80993B/pt not_active IP Right Cessation
- 1985-08-20 DK DK378785A patent/DK378785A/da not_active Application Discontinuation
-
1987
- 1987-09-10 US US07/095,348 patent/US4816489A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE27698T1 (de) | 1987-06-15 |
| EP0174888B1 (fr) | 1987-06-10 |
| FR2569185A1 (fr) | 1986-02-21 |
| US4816489A (en) | 1989-03-28 |
| GR851995B (forum.php) | 1985-12-17 |
| PT80993B (pt) | 1987-09-30 |
| DE3560237D1 (en) | 1987-07-16 |
| ES546860A0 (es) | 1986-03-16 |
| DK378785D0 (da) | 1985-08-20 |
| EP0174888A1 (fr) | 1986-03-19 |
| JPS6165849A (ja) | 1986-04-04 |
| PT80993A (fr) | 1986-02-10 |
| IE851986L (en) | 1986-02-20 |
| FR2569185B1 (fr) | 1986-09-05 |
| DK378785A (da) | 1986-02-21 |
| ES8605467A1 (es) | 1986-03-16 |
| IE58519B1 (en) | 1993-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4177290A (en) | Acetamide derivatives | |
| US3644353A (en) | 4 hydroxy-alpha'aminomethyl-m-xylene-alpha' alpha**3-diols | |
| US4209524A (en) | Acetohydroxamic acids | |
| AU778596B2 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives | |
| US3689524A (en) | Phenethylamine derivatives | |
| IE50878B1 (en) | Propenylamines,processes for their production,pharmaceutical compositions containing them and their use as pharmaceuticals | |
| CH626611A5 (forum.php) | ||
| US3117160A (en) | Aralkylamines | |
| JPH0645595B2 (ja) | ３−フエニル−テトラヒドロピリジン誘導体及びその製造方法 | |
| US3000903A (en) | Phenylalkylhydrazines and use as psychotherapeutics | |
| CA1240993A (en) | 1-(aminophenyl)-2-aminopropanone derivatives | |
| CA1297909C (en) | 1-(aminophenyl)-2-aminoethanone derivatives, the method for their preparation and their use in therapy | |
| US4576944A (en) | 4-Ethyl-2-hydroxy-3-methyl-2-phenylmorpholine, compositions and use | |
| US4407822A (en) | Benzamido-alkyl-hydroxamic acid derivatives | |
| US4680302A (en) | 1-alkyl-3-hydroxy-3-phenylpiperidines | |
| JPS6039069B2 (ja) | アミン誘導体 | |
| US4545996A (en) | N-(4-Acetylaminophenacyl)amine derivatives useful as pharmaceuticals | |
| US4714699A (en) | 2-tolylmorpholine derivatives and pharmaceutical compositions | |
| US3849438A (en) | 2-substituted-3-disubstituted-4,5,6,7-substituted or unsubstituted phthalimidines | |
| US4690950A (en) | 1-[N-(α-amino-α-methylacetyl)aminophenyl]-2-aminopropanone derivatives | |
| GB1586249A (en) | Aminoalkyl-bicycloheptanes | |
| US4713395A (en) | Acetohydroxamic acid derivative | |
| GB1602110A (en) | Acetamidoxime derivatives | |
| IE842902L (en) | (-)-1-(2-fluorophenyl)-2-tertiarybutylamino-1-ehtanol | |
| JPS62240615A (ja) | プロペニルアミンを含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |